Table 1. Variables in the application of HIPEC as a treatment for peritoneal metastases.

Patient-related variables

5 different diseases (colorectal, appendiceal, gastric, and ovarian cancer, malignant peritoneal mesothelioma)

Many unusual indications for CRS and HIPEC

Prevention protocols

Treatment protocols

Extreme treatment protocols

Methodologic variables

HIPEC vs. EPIC, HIPEC + EPIC, EPIC only

No hyperthermia (<41 °C) vs. moderate hyperthermia (≥41-43 °C) vs. extreme hyperthermia (>43-45 °C)

Carrier solution volume—3 L vs. 1.5 L/m2 vs. 6 L

Carrier solution type—saline vs. 1.5% dextrose peritoneal dialysis solution vs. 5% dextrose in water vs. lactated Ringer’s solution vs. dextran solutions

Intraperitoneal irrigations—saline vs. distilled water vs. 0.75% peroxide vs. Betadine

Volume of intraperitoneal irrigation—extensive intraperitoneal lavage (10 L one liter at a time) vs. other

Open vs. closed vs. Coliseum vs. Landager vs. closed then open

Timing—30 vs. 60 vs. 90 vs. 180 minutes

Intraperitoneal epinephrine vs. no epinephrine

Chemotherapy solutions vs. aerosols

Pharmacologic variables

Route of administration—intraperitoneal only vs. intraperitoneal and intravenous

Naked drugs vs. nanoparticles

Single vs. multiple drugs

Mitomycin C

Oxaliplatin

Irinotecan

Cisplatin

Doxorubicin

5-fluorouracil

Melphalan

Gemcitabine

Carboplatin

Docetaxel

Paclitaxel

Pemetrexed

Mitoxantrone

CRS, cytoreductive surgery; HIPEC, hyperthermic perioperative chemotherapy; EPIC, early postoperative intraperitoneal chemotherapy.